CR20200241A - Ligandos de psma para la formación de imágenes y endoradioterapia - Google Patents
Ligandos de psma para la formación de imágenes y endoradioterapiaInfo
- Publication number
- CR20200241A CR20200241A CR20200241A CR20200241A CR20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A
- Authority
- CR
- Costa Rica
- Prior art keywords
- endoradiotherapy
- imaging
- psma
- psma ligands
- compounds
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000163 radioactive labelling Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente divulgación se refiere a la formación de imágenes y endorradioterapia de enfermedades que implican antígeno de membrana específico de próstata (PSMA). Se proporcionan compuestos que unen o inhiben PSMA y adicionalmente llevan al menos una fracción que es susceptible de radiomarcaje. También se porporcionan usos médicos de dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17206510 | 2017-12-11 | ||
| PCT/EP2018/084399 WO2019115547A1 (en) | 2017-12-11 | 2018-12-11 | Psma ligands for imaging and endoradiotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200241A true CR20200241A (es) | 2020-09-21 |
Family
ID=60654872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200241A CR20200241A (es) | 2017-12-11 | 2018-12-11 | Ligandos de psma para la formación de imágenes y endoradioterapia |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11497819B2 (es) |
| EP (2) | EP3723815B1 (es) |
| JP (1) | JP7317375B2 (es) |
| KR (1) | KR20200097690A (es) |
| CN (2) | CN111182927B (es) |
| AU (1) | AU2018382479A1 (es) |
| BR (1) | BR112020011727A2 (es) |
| CA (1) | CA3078104A1 (es) |
| CL (1) | CL2020001542A1 (es) |
| CR (1) | CR20200241A (es) |
| CU (1) | CU24677B1 (es) |
| DK (2) | DK3723815T3 (es) |
| EC (1) | ECSP20029142A (es) |
| ES (1) | ES2914832T3 (es) |
| HR (1) | HRP20220764T1 (es) |
| HU (1) | HUE059083T2 (es) |
| IL (2) | IL274072B1 (es) |
| JO (1) | JOP20200135A1 (es) |
| LT (1) | LT3723815T (es) |
| MX (2) | MX2020005430A (es) |
| PE (1) | PE20210456A1 (es) |
| PL (1) | PL3723815T3 (es) |
| PT (1) | PT3723815T (es) |
| RS (1) | RS63279B1 (es) |
| SG (1) | SG11202002965WA (es) |
| SI (1) | SI3723815T1 (es) |
| TN (1) | TN2020000072A1 (es) |
| UA (1) | UA126413C2 (es) |
| WO (1) | WO2019115547A1 (es) |
| ZA (1) | ZA202003472B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA126413C2 (uk) | 2017-12-11 | 2022-09-28 | Техніше Універзітет Мюнхен | Ліганди psma для візуалізації та ендорадіотерапії |
| PL3917626T3 (pl) * | 2019-01-30 | 2023-11-27 | Technische Universität München | Dwutrybowy radioznacznik i terapeutyk wiążący psma |
| IL303420A (en) * | 2019-01-30 | 2023-08-01 | Univ Muenchen Tech | Diagnostic imaging materials for cancer |
| WO2020252598A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN112321673B (zh) * | 2020-11-04 | 2022-09-20 | 北京市肿瘤防治研究所 | 一种前列腺特异性膜抗原靶向抑制剂及应用和探针 |
| CN113354707A (zh) * | 2021-06-07 | 2021-09-07 | 苏州思萃同位素技术研究所有限公司 | 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品 |
| WO2023173074A2 (en) * | 2022-03-10 | 2023-09-14 | The Research Foundation For The State University Of New York | Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057023A1 (es) | 2005-05-16 | 2007-11-14 | Gilead Sciences Inc | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa |
| CN107382846B (zh) * | 2008-08-01 | 2021-07-06 | 约翰.霍普金斯大学 | Psma-结合剂及其用途 |
| WO2010135431A2 (en) * | 2009-05-19 | 2010-11-25 | The Regents Of The University Of California | Compositions, devices, and methods related to prostate-specific membrane antigen |
| DE202014011600U1 (de) * | 2013-10-18 | 2023-05-31 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs |
| US10683272B2 (en) * | 2014-05-06 | 2020-06-16 | The Johns Hopkins University | Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| CN114716387A (zh) * | 2016-03-22 | 2022-07-08 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| TW201930265A (zh) | 2017-12-11 | 2019-08-01 | 西班牙商阿爾米雷爾有限公司 | 作為acc抑制劑的吡咯衍生物 |
| BR112020010803A2 (pt) | 2017-12-11 | 2020-11-10 | Helsinn Healthcare Sa | sal, (r)-3-(1-(2,3-dicloro-4-(pirazin-2-il)fenil)-2,2,2-trifluoroetil)-1-metil-1-(1-metilpiperidin-4-il) uréia cristalino, produto de medicamento, composição, método para preparar o sal e usos do sal |
| UA126413C2 (uk) | 2017-12-11 | 2022-09-28 | Техніше Універзітет Мюнхен | Ліганди psma для візуалізації та ендорадіотерапії |
-
2018
- 2018-12-11 UA UAA202003533A patent/UA126413C2/uk unknown
- 2018-12-11 JP JP2020526146A patent/JP7317375B2/ja active Active
- 2018-12-11 KR KR1020207014036A patent/KR20200097690A/ko not_active Application Discontinuation
- 2018-12-11 WO PCT/EP2018/084399 patent/WO2019115547A1/en active Application Filing
- 2018-12-11 CU CU2020000052A patent/CU24677B1/es unknown
- 2018-12-11 EP EP18812215.4A patent/EP3723815B1/en active Active
- 2018-12-11 LT LTEPPCT/EP2018/084399T patent/LT3723815T/lt unknown
- 2018-12-11 IL IL274072A patent/IL274072B1/en unknown
- 2018-12-11 ES ES18812215T patent/ES2914832T3/es active Active
- 2018-12-11 DK DK18812215.4T patent/DK3723815T3/da active
- 2018-12-11 IL IL313103A patent/IL313103A/en unknown
- 2018-12-11 CN CN201880056196.2A patent/CN111182927B/zh active Active
- 2018-12-11 BR BR112020011727-7A patent/BR112020011727A2/pt unknown
- 2018-12-11 PE PE2020000552A patent/PE20210456A1/es unknown
- 2018-12-11 CR CR20200241A patent/CR20200241A/es unknown
- 2018-12-11 TN TNP/2020/000072A patent/TN2020000072A1/en unknown
- 2018-12-11 AU AU2018382479A patent/AU2018382479A1/en active Pending
- 2018-12-11 SG SG11202002965WA patent/SG11202002965WA/en unknown
- 2018-12-11 US US16/765,729 patent/US11497819B2/en active Active
- 2018-12-11 PL PL18812215.4T patent/PL3723815T3/pl unknown
- 2018-12-11 JO JOP/2020/0135A patent/JOP20200135A1/ar unknown
- 2018-12-11 EP EP21218180.4A patent/EP4008359B1/en active Active
- 2018-12-11 CA CA3078104A patent/CA3078104A1/en active Pending
- 2018-12-11 RS RS20220527A patent/RS63279B1/sr unknown
- 2018-12-11 PT PT188122154T patent/PT3723815T/pt unknown
- 2018-12-11 DK DK21218180.4T patent/DK4008359T3/da active
- 2018-12-11 MX MX2020005430A patent/MX2020005430A/es unknown
- 2018-12-11 HR HRP20220764TT patent/HRP20220764T1/hr unknown
- 2018-12-11 SI SI201830691T patent/SI3723815T1/sl unknown
- 2018-12-11 HU HUE18812215A patent/HUE059083T2/hu unknown
- 2018-12-11 CN CN202310801735.3A patent/CN116617421A/zh active Pending
-
2020
- 2020-06-03 EC ECSENADI202029142A patent/ECSP20029142A/es unknown
- 2020-06-10 CL CL2020001542A patent/CL2020001542A1/es unknown
- 2020-06-10 ZA ZA2020/03472A patent/ZA202003472B/en unknown
- 2020-07-13 MX MX2023005053A patent/MX2023005053A/es unknown
-
2022
- 2022-07-15 US US17/866,034 patent/US20230122957A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005053A (es) | Ligandos de psma para la formacion de imagenes y endorradioterapia. | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| MX2017016611A (es) | Moduladores de tgr5 y metodos de uso de los mismos. | |
| EA201892430A1 (ru) | Синтез индазолов | |
| UY36757A (es) | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada | |
| PH12020551443A1 (en) | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease | |
| EA201691323A1 (ru) | Анти-vista антитела и фрагменты | |
| TR201909093T4 (tr) | Hidroksi içeren FXR (NR1H4) modüle edici bileşikleri. | |
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201691487A1 (ru) | Антитела человека к pd-l1 | |
| MA34057B1 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
| EP3700917A4 (en) | NEW RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANARY ANTIGEN | |
| WO2015054642A3 (en) | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy | |
| EA201692100A8 (ru) | Новые антитела против rnf43 и способы их применения | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| MA38986B1 (fr) | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| GEP20207106B (en) | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer | |
| EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
| PH12019502694A1 (en) | Anti-trkb antibodies |